C
Claudia Mandato
Researcher at Boston Children's Hospital
Publications - 77
Citations - 1681
Claudia Mandato is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Liver disease. The author has an hindex of 16, co-authored 59 publications receiving 1274 citations. Previous affiliations of Claudia Mandato include University of Naples Federico II & University of Salerno.
Papers
More filters
Journal ArticleDOI
Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease.
Pietro Vajro,Claudia Mandato,Maria Rosaria Licenziati,Adriana Franzese,Dino Franco Vitale,S. Lenta,M. Caropreso,Gianfranco Vallone,Rosaria Meli +8 more
TL;DR: Probiotic L rhamnosus strain GG warrants consideration as a therapeutic tool to treat hypertransaminasemia in hepatopathic obese children noncompliant with lifestyle interventions.
Journal ArticleDOI
Vitamin E treatment in pediatric obesity-related liver disease: a randomized study.
Pietro Vajro,Claudia Mandato,Adriana Franzese,E Ciccimarra,S. Lucariello,Marcella Savoia,G. Capuano,Fiorella Migliaro +7 more
TL;DR: Oral vitamin E warrants consideration in obesity-related liver dysfunction for children unable to adhere to low-calorie diets and two subgroups of patients with complete normalization of transaminase values emerged as a consequence of controlled adherence to diet alone and to vitamin E alone.
Journal ArticleDOI
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
TL;DR: Several lines of evidence are presented indicating that, by increasing energy extraction in some dysbiosis conditions or small intestinal bacterial overgrowth, specific gut microbiota and/or a "low bacterial richness" may play a role in obesity, metabolic syndrome, and fatty liver.
Journal ArticleDOI
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
TL;DR: A liver biopsy is required for a definitive NAFLD/NASH diagnosis, particularly to exclude other treatable conditions or when advanced liver disease is expected on clinical and laboratory grounds and preferably prior to any controlled trial of pharmacological/surgical treatments.